Premium
The murine Fc‐gamma (Fcγ) receptor type II B1 is a tumorigenicity‐enhancing factor in polyoma‐virus‐transformed 3T3 cells
Author(s) -
Zusman Tal,
Gohar Ofra,
Eliassi Ilan,
Avivi Yechiam,
Lisansky Ellen,
Sautes Catherine,
Even Jos,
Bonnerot Christian,
Fridman Wolf H.,
Witz Isaac P.,
Ran Maya
Publication year - 1996
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19960117)65:2<221::aid-ijc16>3.0.co;2-g
Subject(s) - transfection , biology , receptor , microbiology and biotechnology , 3t3 cells , in vitro , fc receptor , immune system , cell culture , immunology , biochemistry , genetics
The murine receptor for the Fc portion of IgG is a molecule expressed by cells of the immune system. This study suggests the hypothesis that Fcγ receptor type II B1 (FcγRIIB1) functions as a progression‐enhancing factor when expressed ectopically on non‐lymphoid tumor cells. It has been shown previously that BALB/c 3T3 cells transformed in vitro with polyoma virus (PyV) do not express FcγRII but acquire the expression of this receptor following an in vivo passage in syngeneic mice. The specific FcγRII transcript present in tumor cells was identified in this report as FcγRIIB1 (B1). In order to determine whether or not the ectopically expressed FcγRII plays a role in the progression of these transformed cells, PyV‐transformed 3T3 cells were transfected with B1‐cDNA. The B1 transfected cells were tested for their ability to form local tumors in syngeneic mice, as compared to transfected cells which express the co‐transfecting neomycine resistance (neo res ) DNA alone or together with the lacZ gene. FcγRIIB1 expressors exhibited a significantly higher tumorigenic phenotype than FcR‐negative controls, though both types of cells exhibited the same growth curve in vitro. The ability of FcγRIIB1 to act as a potentially tumorigenicity‐enhancing factor was also demonstrated as FcγRII was expressed by tumor cells, originating from inoculated FcγRIIB1‐transfected cells, or from inoculation of a mixture of receptor‐positive and ‐negative cells. B1‐expressing cells dominated the tumor‐cell population over non‐expressors. This dominance strengthened the hypothesis that FcR plays a role in tumor progression in vivo. © 1996 Wiley‐Liss, Inc.